-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Author Index: A

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
1538 - WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML)
1539 - Predictive Analysis on Prognostic Impact of Monosomy 7 in AML and Identified Therapy Options for This Cohort
1540 - Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study
1541 - Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study
1893 - Clinical Validation of Treatment Response Predictions Using a Genomics Driven Computational Biology Modelling Multiple Myeloma Algorithm
1911 - Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome
3086 - Analysis of the Evolving MDS/AML Clones to Identify Resistance Mechanisms and Predict New Therapy Options at Relapse Using Computational Biology Modeling: Case-Studies from iCare1 Clinical Study
3087 - Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System
3193 - Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics
4034 - AraC-Daunorubicin-Etoposide (ADE) Response Prediction in Pediatric AML Patients Using a Computational Biology Modeling (CBM) Based Precision Medicine Workflow
49 - Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms
87 - Hematologic Malignancies Arising in Patients with Germ Cell Tumors: Secondary Somatic Differentiation of Hematopoietic Malignancies from Germ Cell Precursors
233 - Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents
385 - Leukemia Risk Gene ARID5B is a Crucial Regulator of B-Cell Development
392 - Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl
427 - Therapeutic Targeting of an RNA Splicing Factor Network for the Treatment of Myeloid Neoplasms
541 - High Throughput Droplet Single-Cell Genotyping of Transcriptomes (GoT) Reveals the Cell Identity Dependency of the Transcriptional Output of Somatic Mutations
654 - Crispri-Based Screening of Clustered Regulatory Elements Reveals Novel Leukemia Dependencies
882 - Mutations in the RNA Splicing Factor SF3B1 Promote Transformation through MYC Stabilization
937 - Dependency of Spliceosomal Mutant MDS on Innate Immune Signaling
938 - Specific Bone Marrow Mesenchymal Subsets in Patients with Myelodysplastic Syndromes Harbor Molecular Perturbations That Alter the Dynamics of Competition between Pre-Leukemic Clones and Normal Cells
1312 - Multimodal Single-Cell Profiling Defines the Epigenetic Determinants of Chronic Lymphocytic Leukemia Evolution
1796 - RUNX1 Deficiency Cooperates with SRSF2 Mutation to Further Disrupt RNA Splicing and Exacerbate Myelodysplastic Syndromes in Mouse Models
2397 - The Role of microRNAs in the Pathogenesis of Erdheim-Chester Disease and Their Potential Use As Biomarkers for Diagnosis and Prognosis of the Disease
43 - Gimema Registry of Conception/Pregnancy in Adult Italian Patients Diagnosed with Chronic Myeloid Leukemia (CML): Report on 166 Outcomes
44 - The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients
458 - Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis
461 - Imatinib Suspension and Validation (ISAV) Study: Final Results at 79 Months
1726 - Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Induces Genetic Instability and Can be Therapeutically Targeted
1729 - Pregnancy Outcomes in Patients Treated with Bosutinib
1732 - One Size Does Not Fit to All: Intolerant or Resistant CML Patients Could Benefit from Different Ponatinib Starting Dose Strategies. Multicenter Italian Experience
1750 - International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. a Gimema and HOVON Study
3006 - Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors
3012 - Comparative Monitoring of Minimal Residual Disease (MRD) By RT-Quantitative (RT-qPCR) and Digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) Patients Treated with TKIs for Recognition of Stable Deep Molecular Response (DMR) and Identification of Best Candidates to TKIs Treatment Discontinuation
3021 - Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients
3052 - Presentation and Outcome of 199 Patients with 2016 Who Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib
4078 - Next Generation Sequencing-Based BCR-ABL1 Kinase Domain Mutation Screening in De Novo and Tyrosine Kinase Inhibitor-Resistant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study
4244 - Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Level. Comparison of Qpcr, d-PCR and CD26 Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR)
4251 - First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0 / MR4.0 Stable Molecular Response
4254 - Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy
4255 - Chronic Myeloid Leukemia Diagnosed during Pregnancy: Therapy, Outcomes and Follow-up
4263 - Kinetics of BCR-ABL after TKI Interruption during Pregnancy in CML: A Multinational Retrospective Analysis
4277 - Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients
4312 - Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI)
33 - Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia
211 - Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies
331 - Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative and Subgroup Analyses
371 - Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States
712 - Pharmacist Interventions on Outpatient Leukemia Patients Improve Safety
900 - Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?
1389 - Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy
1527 - Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia
1797 - Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes
2075 - Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia
2270 - TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of Cancer
2298 - Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States
2590 - Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia
2699 - Comparison of CD22 Expression between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials
3084 - Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential
3869 - Impact of Eltrombopag on Clonal Evolution in Refractory Aplastic Anemia
4031 - Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study
4353 - Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML
4603 - Risk Factors for Early Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia
4768 - Adolescent and Young Adult (AYA) Hematopoietic Cell Transplantation (HCT) Recipients Have Similar Quality of Life (QoL) Compared to Older Adults in the First Year Post-Transplantation
4805 - Risk of Venous Thromboembolism in Acute Leukemias: A Meta-Analysis
4806 - Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay
93 - Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy
451 - Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers
615 - No Utility of Routine Laboratory Testing during Surveillance in Detecting Relapse in Patients with Classic Hodgkin Lymphoma in First Remission
623 - Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F)
679 - A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I)
997 - The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas
1615 - The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imid® Continuation (BIONIC) Study
1626 - Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy
1635 - Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)
1651 - A Phase II Study of Sequential Pembrolizumab (PEM) Followed By AVD for Frontline Treatment of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following PEM Monotherapy with FDG-PET-Derived Metabolic Tumor Volume and Total Lesion Glycolysis
1690 - Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes
2838 - Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma
2861 - Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing
2888 - Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia
2899 - Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy for Patients with Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results
2904 - Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study
2937 - Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study
4157 - A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408
- Risk-Adapted Upfront Therapy for Hodgkin Lymphoma in 2018
2012 - Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab
2243 - Real-World Outcomes for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone, or Bortezomib and Dexamethasone: An Enhanced Electronic Health Records Database Analysis
3161 - Comprehensive Immune Profiling from Peripheral Blood and Bone Marrow in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma Patients Reflects Differences in Immune Subsets and Activation Status
3232 - Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect® MM Registry
3245 - Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma
3271 - Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure
3535 - Cost-Effectiveness Analysis of Lenalidomide for Maintenance Therapy after Autologous Stem Cell Transplant (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) Patients: A United States Payer Perspective
4729 - The Current Situation of Multiple Myeloma Treatment in Japan: A Cross-Sectional Analysis Based on Health Insurance Claims Data
4770 - Burden of CRAB Events By Relapse in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Stem Cell Transplant
622 - Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia
1606 - Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting
1911 - Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome
3232 - Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect® MM Registry
3244 - Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines
4138 - Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF)
4141 - Depth of Response in Waldenstrom Macroglobulinemia
4764 - Timeliness of Initial Therapy in Multiple Myeloma (MM): Trends and Factors Influencing Patient Care
4765 - Trends in the Utilization of Radiation Therapy (XRT) Among Patients with Non-Hodgkin's Lymphoma (NHL) in the United States (US)
4852 - Impact of Depression or Anxiety on Opioid and Benzodiazepine Use in Hospitalized Hematopoietic Stem Cell Transplantation (HSCT) Recipients
4861 - Disparity in Clinical Trial Opportunities for Patients with B-Cell Malignancies in the United States
4867 - Exploring Disease Biology in Hispanic Versus Non-Hispanic Patients with Diffuse Large B-Cell Lymphoma (DLBCL) to Explain Survival Disparities
4868 - Sociodemographic Profile and Outcomes of Patients with Non-Diffuse Large B-Cell Lymphoma (non-DLBCL) Treated at Minority-Predominant Facilities in the United States
4869 - Trends in the Risk of Second Primary Malignancies (SPMs) Among Survivors of Chronic Lymphocytic Leukemia(CLL)
33 - Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia
334 - Response to Venetoclax and Hypomethylating Agents Among Prognostic Risk Groups and Genetic Subtypes of Acute Myeloid Leukemia
1338 - Downregulation of Mir-142 Promotes Leukemia Growth in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): A Possible Novel Therapeutic Target?
1411 - Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors
1549 - Cytokine Gene Polymorphisms Are Associated with Disease Response to Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia
1552 - Genomic Determinants of Response to Blinatumomab in Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia in Adults
1752 - MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis
2181 - Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation
2816 - Clinical, Cytogenetic and Immunophenotype Distribution of Adult Acute Lymphoblastic Leukemia Among Latinos – a Report from a Large Single Institution Cohort in Southern California
3386 - Effect of Vancomycin-Resistance Enterococci Colonization Status Prior to Allogeneic Hematopoietic Cell Transplantation on Transplant Outcomes: A Single Center Retrospective Experience
3416 - Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide – Possible Role of Donor KIR Genotypes
392 - Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl
437 - Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial
561 - Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study
564 - Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)
688 - Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis
1458 - Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations
1706 - Clinical Outcomes of Venetoclax Therapy in Patients with Relapsed/Refractory (r/r) Non Hodgkin Lymphomas (NHL)
- The Clock is Ticking: managing acute leukemia in the first 24 hrs
- Tumor Board Panelist
36 - Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study
84 - Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study
186 - Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL)
230 - Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients
232 - Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)
286 - Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome
465 - A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)
905 - Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
906 - Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study
1438 - Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant Myelodysplastic Syndrome (MDS)
1831 - Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)
2667 - Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations
2674 - Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study
2715 - Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations
2722 - Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
3985 - Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia
4039 - Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia
4367 - Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab
1839 - Remarkable Functional Constraints on the Antigen Receptors of CLL Stereotyped Subset #2: High-Throughput Immunogenetic Evidence
1843 - RPS15 mutations Repress mRNA Translation in Chronic Lymphocytic Leukemia Cells
2057 - High-Throughput T Cell Receptor (TR) Repertoire Analysis of Virus-Specific T Cells: Implications for T Cell Immunotherapy and Viral Infection Risk Stratification
2193 - Thalassemia Gene Therapy By In Vivo Transduction of Mobilized Hematopoietic Stem Cells (HSCs) with an Integrating Hybrid Adenovirus Vector System
3107 - Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry
3110 - The Transcription Factor TAp63 Exerts Pro-Survival Effects in Chronic Lymphocytic Leukemia Acting through the BCL2 Pathway
3295 - Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group
3401 - Pre-Transplant Genetic Susceptibility in Adult Allogeneic Hematopoietic Cell Transplant Recipients: Incidence and Clinical Relevance in Transplant-Associated Thrombotic Microangiopathy
3429 - Second Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
4400 - Longitudinal High-Throughput T Cell Repertoire Profiling of Chronic Lymphocytic Leukemia Patients Under Different Types of Treatment: Implications for Combination Strategies
60 - Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma
109 - The Landscape of Structural Variant Signatures in Multiple Myeloma Identifies Distinct Disease Subgroups with Implications for Pathogenesis
154 - Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
190 - Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma
244 - Plasmacytoid Dendritic Cells Trigger Contact-Dependent Tumor Promoting Genetic Alterations in Multiple Myeloma Cells
407 - APOBEC3B Is Induced By Activation of DNA Repair Pathway and Modulates the Survival and Treatment Response in Human Multiple Myeloma
592 - Anti-Bcma BiTE® AMG 701 Potently Induces Specific T Cell Lysis of Human Multiple Myeloma (MM) Cells and Immunomodulation in the Bone Marrow Microenvironment
594 - Identification of Alpha-Enolase (ENO1)­ As a Novel Immunometabolic Target in Multiple Myeloma
749 - The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome
804 - Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
1313 - Chromatin Accessibility Profiling Reveals Cis-Regulatory Heterogeneity and Novel Transcription Factor Dependencies in Multiple Myeloma
1917 - Genome-Wide CRISPR-Cas9 Screening Reveals a Role for TRAF2 in Resistance to IMiDs in Multiple Myeloma
1925 - Functional Role of Linc-RNAs in Multiple Myeloma: Linc-MIR17HG Affects Fatty Acid Biosynthesis Via transcriptional Regulation of ACC1 with Potential Therapeutic Implications
1930 - Targeting Tryptophan Catabolic Kynurenine Pathway Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple Myeloma
1932 - Optimizing Mechanisms for Induction of Immunogenic Cell Death to Improve Patient Outcome in Multiple Myeloma
1939 - The Critical Role of HDAC1-IRF4-Pim-2 Axis in Myeloma Cell Growth and Survival: Therapeutic Impacts of Targeting the HDAC1-IRF4-Pim-2 Axis
3156 - Targeting Distinct Promoter- and Enhancer-Driven Dependencies in Multiple Myeloma
3171 - Deciphering the Chronology of Copy Number Alterations in Multiple Myeloma (MM): What Comes First?
3176 - Dysregulated Translational Control Is a Central Feature of MM Mediated By 14-3-3ε Interactome Promoting Multiple Myeloma Cell Growth and Viability
3195 - Bcma Heteroclitic Peptide Encapsulated Nanoparticle Enhances Antigen Stimulatory Capacity and Tumor-Specific CD8+ cytotoxic T Lymphocytes Against Multiple Myeloma
3196 - Selective Targeting of Multiple Myeloma By Bcma-Specific Central Memory CD8cytotoxic T Lymphocytes: A Potential Immunotherapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders
3209 - APRIL Is Significantly Elevated at All Stages of Multiple Myeloma (MM) and Interferes with Anti-Bcma Monoclonal Antibody-Mediated Cytolysis, Supporting the Clinical Evaluation of Bion-1301 As a Novel Therapeutic Approach in MM
3211 - Blockade of Ubiquitin Receptor PSMD4/Rpn10 Triggers Cytotoxicity and Overcomes Bortezomib-Resistance in Multiple Myeloma
3263 - A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
3895 - Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML)
4440 - JAK-STAT3 Pathway Regulates CD38 Expression on Multiple Myeloma Cells
4737 - Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance 100104)
- Introduction of Speaker
86 - Acute Myeloid Leukemia Expands Osteoprogenitor Rich Niche in the Bone Marrow but Resorbs Mature Bone Causing Osteopenia/Osteoporosis in Animal Models
88 - Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML)
286 - Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome
430 - Mitochondrial Transfer Confers Microenvironment-Mediated Resistance to Oxphos Inhibition in AML
663 - Outcomes with Subsequent FLT3-Inhibitor (FLT3i) Based Therapies in FLT3-Mutated (mu) Patients (pts) Refractory/Relapsed (R/R) to One or More Prior FLT3 Inhibitor Based Therapies: A Single Center Experience
767 - Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study
768 - Mcl-1/CDK9 Targeting By AZD5991/AZD4573 Overcomes Intrinsic and Acquired Venetoclax Resistance in Vitro and In Vivo in PDX Model of AML through Modulation of Cell Death and Metabolic Functions
890 - Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL
912 - Single-Cell Mass Cytometry Characterizes Phenotypic and Functional Heterogeneity in Acute Myeloid Leukemia at Diagnosis, in Remission and Relapse
1441 - Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
1442 - Targeting Wnt/β-Catenin and BCL-2, Two Critical Survival Factors, Synergistically Induces Apoptosis in AML Via Rac1-Mediated MCL-1 Inhibition
1479 - Diverse Landscape of TET2 Variants in MDS and AML
2544 - Granulocyte Transfusions for Neutropenic Patients with Perirectal and Perineal Infections
2625 - Genetic Dissection of p53 Driven Senescence of Bone Marrow Mesenchymal Cells in Acute Myeloid Leukemia
2629 - TP73 Isoforms (TAp73 and ΔNp73) Are Overexpressed in Acute Myeloid Leukemias and Potential Therapeutic Targets to Enhance Anti-Leukemia Activities of Bcl-2 and MDM2 Inhibitors
2635 - Concomitant Targeting of FLT3 and BTK with CG'806 Overcomes FLT3-Inhibitor Resistance through Inhibition of Autophagy
2640 - Combined Targeting of Bcl-2 and XPO1 Overcomes Acquired Resistance to Tyrosine Kinase Inhibitors in the FLT3-ITD/TKD Double Mutant AML
2642 - TAM Inhibitor ONO-7475 Combination with Sorafenib Is Effective Using in Vitro and In Vivo Models of FLT3 ITD Acute Myeloid Leukemia
2686 - AXL Expression in Pediatric AML Is Associated with Putative LSC and Correlates with a Distinct Set of Proteins Associated with Cell Metabolism, Cell Cycle, and Unfolded Protein Response
2714 - Phase 2 Study of Lenalidomide Maintenance for Patients with High-Risk Acute Myeloid Leukemia in Remission
2715 - Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations
2720 - Synergistic Anti-Leukemic Activity with Combination of FLT3 Inhibitor Quizartinib and MDM2 Inhibitor Milademetan in FLT3-ITD Mutant/p53 Wild-Type Acute Myeloid Leukemia Models
2724 - IL15 Expressing CD123-Targeted Engager T-Cell Therapy for Adult Acute Myeloid Leukemia
2757 - Distinct Gene Expression Patterns of Minimal Residual Disease (MRD) Cells in High-Risk AML Patients Identified By RNA-Sequencing
2768 - CD200 Is a Stem Cell-Specific Immunosuppressive Target in AML
2791 - Landscape of TP53 Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia
3689 - Characteristics and Outcomes of Patients (pts) with Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) in Adults: A Single-Center, Prospective Analysis of 36 Pts
3815 - Safety and Efficacy of Non-Irradiated Granulocyte Transfusions (GTX) in Neutropenic Patients with Severe or Refractory Abdominal Infections: A Single Center Retrospective Analysis of 119 Transfusions in 22 Patients
3934 - Targeting Autophagy Kinase ULK1 Can Reverse Bcl2 Inhibitor (ABT-199) Induced Autophagy to Overcome Acquired Resistance in Acute Myeloid Leukemia
3944 - Upregulation of Bcl-2 Confers Resistance to FLT3 Inhibition in FLT3-ITD AML with Secondary Acquired Mutations
3976 - Survivorship in AML - Outcomes of Acute Myelogenous Leukemia (AML) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years (yrs)
3996 - Potential Predictors of Induction Failure and Complete Remission Duration in FLT3-ITD Mutated Acute Myeloid Leukemia
4039 - Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia
4367 - Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab
168 - Hematopoietic Cell Transplantation in Thalassemia and Sickle Cell Disease: Report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry: 2000-2017
234 - Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int-1-Risk Myelodysplastic Syndromes (MDS): Outcomes from the Randomized, Double-Blind Telesto Study
485 - Prediction of Leukemia-Free Survival Following Haploidentical Stem Cell Transplantation in Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
789 - Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing
1687 - R-CHOP Preceded By Engineered Tumor Necrosis Factor (TNF) in Patients with Relapsed or Refractory (r/r) Primary CNS Lymphoma (PCNSL): Results of Antitumor Activity, Safety and Blood-Brain Barrier (BBB) Permeabilization in the “Ingrid” Phase II Trial
3351 - Unmanipulated Haploidentical Marrow Transplantation with a Modified Post-Transplant Cyclophosphamide (PT-CY) Regimen: An Update on 444 Patients
3369 - Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia: On Behalf of Eurocord, Ctiwp and PDWP of EBMT
3475 - Outcomes after Unrelated Cord Blood Transplantation (UCBT) in Patients with Chronic Myeloid Leukemia (CML): A Retrospective Study from the Cmwp-EBMT
4586 - Graft-Versus-Leukemia Effect after Haplo-Identical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with AML- No Association with Graft-Versus-Host Disease: A Study on Behalf of the Acute Leukemia Working Party of EBMT
454 - Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era
456 - Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD)
586 - PD-1 Overexpression in Richter's Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway
622 - Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia
623 - Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F)
679 - A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I)
1590 - Tigit Expression Defines a Subset of Activated Treg Cells with Prognostic Relevance in Follicular Lymphoma
1606 - Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting
1609 - Ibrutinib for the Treatment of Bing-Neel Syndrome
1618 - Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study
1620 - A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data
1635 - Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)
1690 - Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes
2247 - An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation
2884 - Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia
2897 - Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study
2899 - Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy for Patients with Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results
2904 - Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study
2921 - Resolution of Peripheral Neuropathy (PN) in Patients Who Received A+AVD or ABVD in the Phase 3 ECHELON-1 Trial
2932 - Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study
3430 - Infusion of NKp30/KIR2DL2 Natural Killer Cell Ratio and Survival Post-Autologous Stem Cell Transplantation in Lymphomas
4134 - Prevalence and Regulation of Effector CD8+ T Cell Subsets in B-Cell NHL
4138 - Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF)
4141 - Depth of Response in Waldenstrom Macroglobulinemia
4152 - Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model
4204 - Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL
1432 - A Network Meta-Analysis of Clinical Trials Assessing Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Among Young Adults
1948 - Efficacy and Toxicity Profile of Ibrutinib Based Regimens for Refractory Multiple Myeloma: A Systematic Review
1949 - Promising Clinical Efficacy and Toxicity Profile of Isatuximab Based Regimens for Treatment of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: A Systematic Review
1950 - Clinical Efficacy of Intracellular Molecular Inhibitors for Relapsed, Refractory Multiple Myeloma: A Systematic Review of Early Clinical Data
1951 - Presentation Patterns and Management Strategies for Central Nervous System Involvement in Multiple Myeloma: A Systematic Review of Literature
1952 - Evidence Based Recommendations for Supportive Care in Multiple Myeloma
2022 - Pomalidomide Based Regimens for Treatment of Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials
2025 - Efficacy and Tolerability of Daratumumab in Heavily Pretreated AL Amyloidosis: A Systematic Review
2194 - Gene Therapy for Thalassemia and Sickle Cell Anemia Poses Acceptable Toxicity and Efficacy: Clinical Outcomes in Forty-Seven Cases
3239 - Efficacy of Lenalidomide Based Three Drug Versus Two Drug Regimen for Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Trials
3292 - Efficacy and Safety of Daratumumab Based Regimens for Multiple Myeloma: A Systematic Review and Meta-Analysis
3309 - Presentation Pattern, Diagnostic Markers, Management and Outcome of IgD Multiple Myeloma: A Systematic Review
3562 - The Healthcare Burden of Emergency Department Utilization for Multiple Myeloma: A Five Years U.S Nationwide Study
4695 - National Trends in Leukemia Related Emergency Department Visits, Health Care Burden and Disposition Rate in the United States, 2010-2014
4835 - Venous Thromboembolism with Contemporary Lenalidomide-Based Regimens and Adequate Thromboprophylaxis in Newly Diagnosed Multiple Myeloma: A Systemic Review and Meta-Analysis
293 - RPPA-Profiling Identifies Patients with Low Phosphorylation Levels of HSF1 at Serine 326 As Potential Candidate for Bortezomib Treatment in Addition to Standard Therapy in Pediatric Acute Myeloid Leukemia
294 - Proteomic Landscape of De Novo Pediatric Acute Myeloid Leukemia
369 - Increased Disease Burden Among Black Children Compared to White Children with Newly Diagnosed Acute Myeloid Leukemia
624 - Using Administrative Data to Identify Relapse and Hematopoietic Stem Cell Transplantation (HSCT) in Children with Acute Lymphoblastic Leukemia (ALL): Validation at Two Centers and Incidence Estimation in a National Cohort
830 - Comparative Effectiveness of Rasburicase and Allopurinol in Children with Acute Lymphoblastic Leukemia: An Emulated Pragmatic Trial Using Observational Data
833 - Assessing Neighborhood Characteristics As Risk Factors for Bloodstream Infection in Children with Acute Leukemia
881 - Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options – a COG and Target Pediatric AML Study
1383 - Comparing the Liver Function of Children with Acute Lymphoblastic Leukemia (ALL) Receiving Standard or High Intensity Treatment during the Interim Maintenance I Phase of Therapy: A Study of 658 Patients
1405 - Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia
1490 - Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531
2290 - Pediatric Patient-Reported Symptom Tracking in Oncology (Pedi-PReSTO): A Feasibility Study
3597 - A Novel Approach to Identifying Septic Shock (SS) in Children with Acute Lymphoblastic Leukemia (ALL) Using Pediatric Health Information System (PHIS) Data: Methods Validation and Incidence Estimation in a National Cohort
3979 - Safety of Gemtuzumab Ozogamicin As Monotherapy or Combination Therapy in an Expanded-Access Protocol for Patients with Relapsed or Refractory Acute Myeloid Leukemia
4763 - Evaluation of Hospital Admission Patterns in Children Receiving Treatment for Acute Lymphoblastic Leukemia: What Does a Typical Leukemia Experience Look like?
4841 - Quality of Life in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
457 - Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML
1517 - "Function First" Screen of Primary AML Cells Identifies Common and Personalised Therapeutic Targets
1738 - DNA-Based Digital PCR for the Quantification of Residual Disease in CML – Sensitivity or Specificity?
2139 - Conception and Pregnancy Outcomes after Haematopoietic Stem Cell Transplant: A Retrospective Study from the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation
3007 - Dose Reduction of First and Second Generation TKIs Is Effective in the Maintenance of Major Molecular Response and May Predict Successful Tfr in CML Patients
3417 - Incidence and Risk Factors for Second Malignancies after Transplant in Long Term Survivors of Allogeneic Haematopoietic Stem Cell Transplant: A Single Centre Experience
4254 - Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy
4263 - Kinetics of BCR-ABL after TKI Interruption during Pregnancy in CML: A Multinational Retrospective Analysis
4492 - Clustering Analysis of Myeloma Clone Phenotype Is Informative for Disease Heterogeneity and Prognosis at Relapse
4650 - Complete Remission with Incomplete Count Recovery (CRi) Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Is Associated with a High Non-Relapse Mortality without Increased Relapse Risk
- The Argument for Using Imatinib in CML
49 - Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms
292 - Molecular Predictors and Current Management of Minimal Residual Disease (MRD) Following Induction Chemotherapy for Acute Myeloid Leukemia (AML)
1983 - MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone
2788 - PHF6 Mutations Are Mutually Exclusive to TP53 Mutations, and Define a Distinct Subgroup of Secondary Acute Myeloid Leukemia Associated with a Primitive Stem/Progenitor Immunophenotype, Absent Complex Karyotype and Relatively Better Outcomes
2789 - Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation: Predominantly Secondary AML, Enriched for RUNX1 Mutations, Frequent Cross-Lineage Antigen Expression and Poor Prognosis
3077 - Myeloid/Histiocytic Neoplasms Associated with Germ Cell Tumors Harbor Shared Genetic Abnormalities Indicating a Clonal Relationship, Unique Molecular Pathogenesis and Cellular Origin
3281 - Bone Marrow-Based and Longitudinal Blood-Based MRD Tracking in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd): A Correlative and Clinical Phase II Study
4444 - V(D)J Sequence Capture for DNA-Based Minimal Residual Disease Detection in Multiple Myeloma
4475 - Next-Generation Sequencing-Based Assay Shows High Clonal Characterization Success Rate for Plasma Cell Neoplasms, and Concordance with Flow Cytometry in Minimal Residual Disease Detection
398 - Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
402 - The iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma
572 - Real-World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival
1679 - Study of AUTO3, the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22, Followed By Anti-PD1 Consolidation in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Alexander Study
2874 - Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study
2956 - A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial
3130 - Cytotoxic CD4+ Cells in Chronic Lymphocytic Leukaemia: An Extended Immunophenotypic Analysis Examining Their Association with Cytomegalovirus Serostatus and Similarities with Cytotoxic CD8+ Cells
4167 - Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMOTM Clinical Trial in iNHL
4227 - Encouraging Clinical Outcomes for Lymphoma Patients Participating in Early Phase Clinical Trials in the Current Era: A Single Institution and a Global Perspective
92 - Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity
93 - Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy
145 - Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience
228 - Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies
678 - Analysis of CAR-T and Immune Cells within the Tumor Micro-Environment of Diffuse Large B-Cell Lymphoma Post CAR-T Treatment By Multiplex Immunofluorescence
705 - A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT)
706 - PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation
1559 - Comprehensive Genomic Analysis of Flow-Sorted Hodgkin Reed Sternberg Cells Reveals Additional Genetic Bases of Immune Evasion
1579 - Integrated Genetic and Topological Analysis Reveals a Hodgkin-like Mechanism of Immune Escape in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
1620 - A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data
1626 - Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy
1650 - PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
1654 - A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma
2177 - Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma
2897 - Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study
2900 - Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma
2932 - Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study
4216 - Procalcitonin As a Potential Biomarker for Differentiating Bacterial Infectious Fevers from Cytokine Release Syndrome
110 - Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma
114 - The Mutational Landscape of Primary Plasma Cell Leukemia
408 - Chromothripsis and Chromoplexy Are Associated with DNA Instability and Adverse Clinical Outcome in Multiple Myeloma
1882 - Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies
1906 - Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches
1929 - Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors
3165 - A High-Risk Multiple Myeloma Group Identified By Integrative Multi-Omics Segmentation of Newly Diagnosed Patients
3185 - Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma
3897 - High Levels of APOBEC3B Gene Expression Contribute to Poor Prognosis in Multiple Myeloma Patients
3904 - Global 3D-Epigenetic Dysregulation of Cyclin D1 and D2 Actively Controls Their Expression Pattern in Multiple Myeloma
4441 - Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53
4454 - Hotspot Mutations in SF3B1 Result in Increased Alternative Splicing in Multiple Myeloma and Activation of Key Cellular Pathways
4456 - Mutations and Copy Number Changes Predict Progression from Smoldering Myeloma to Symptomatic Myeloma in the Era of Novel IMWG Criteria
4457 - Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior
93 - Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy
184 - MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
399 - Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study
453 - Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy
461 - Imatinib Suspension and Validation (ISAV) Study: Final Results at 79 Months
767 - Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study
1626 - Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy
1683 - Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study
2256 - Hepatitis B Virus (HBV) Screening and Associated Outcomes in Malignant Hematology Patients Receiving Rituximab Therapy within the Rossy Cancer Network
4097 - Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study
68 - Prediction of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Using a Machine Learning Algorithm
108 - Novel and Significant Impact of Germline Variants Predisposed to Pathogenic Somatic Mutations and Loss of Heterozygosity (LOH) in Myelodysplastic Syndromes (MDS) and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
250 - Risk Factors and Predictive Scoring System for Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation
438 - Prospective Evaluation of Prognostic Relevance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: Results from the JALSG CBF-AML209-KIT Study
2097 - Impact of Homozygous Conserved Extended HLA Haplotypes on Cord Blood Transplantation: Implications for Induced Pluripotent Stem Cell Banking and Transplantation
2173 - Hematopoietic Stem Cell Transplantation in Children with Refractory Acute Lymphoblastic Leukemia
2798 - CD56 Is an Unfavorable Prognostic Factor for Acute Promyelocytic Leukemia: Results By Multivariate Analyses in the JALSG-APL204 Study
3008 - Reduced-Intensity Allogeneic HSCT for Children and Adolescents/Young Adults with CML: A Study from the Adult and Pediatric CML Working Group of the Japan Society for Hematopoietic Cell Transplantation
3437 - Efficacy and Safety of Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma in the Era of Novel Agents
3452 - Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Myelodysplastic Syndrome in Adolescent and Young Adult Patients
3453 - Epidemiology of Second Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed Myelodysplastic Syndrome
3461 - Effect of Haplotype Matching on Outcomes after Adult Single Cord Blood Transplantation
3466 - Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Primary Myelofibrosis Among Stem Cell Source Groups
4209 - Impact of Prophylactic Antiviral Therapy on Clinical Outcomes of Hepatitis B Virus Surface Antigen Positive Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab-Containing Chemotherapy
4631 - Mixed Chimerism and Secondary Engraftment Failure in Allogeneic Transplantation for Aplastic Anemia
4632 - Hematopoietic Stem-Cell Transplantation in Children with Refractory Acute Myeloid Leukemia
4635 - Who Is the Best Donor for the Second Transplant?: HLA Discrepancy between Graft and Host Rather Than That Graft and First Donor May Impact the Second Transplant Outcome from the JSHCT
4641 - Impact of Pretransplant HTLV-1 Seropositivity on Hematopoietic Stem Cell Transplantation for the Diseases Other Than ATLL- an Analysis on Behalf of JSHCT Complication Working Group-
4644 - Comparable Survival Outcomes of Haploidentical Stem Cell Transplantation and Unrelated Bone Marrow Transplantation
4669 - Would Bone Marrow be Associated with Superior Outcomes Compared with Peripheral Blood for Male Recipients with Female Donors in HLA-Matched Related Transplantation?
4671 - Hematopoietic Cell Transplantation for Children with Acute Megakaryoblastic Leukemia without Down Syndrome
59 - Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma
111 - Analysis of Sequential Patient Samples from the Mmrf Commpass Study Identifies a High Risk Progression Phenotype
113 - An Integrated Genomics Analysis Identifies Recurrent Gain- and Loss-of-Function Events and in Distinct Subtypes of Multiple Myeloma
154 - Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
189 - Functional Genomic Landscape of Genes with Recurrent Mutations in Multiple Myeloma
405 - Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy
408 - Chromothripsis and Chromoplexy Are Associated with DNA Instability and Adverse Clinical Outcome in Multiple Myeloma
614 - Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability?
749 - The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome
799 - Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Commpass Study
951 - Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function
1367 - CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias
1895 - Development and Validation of a High Risk Multiple Myeloma Gene Expression Index from RNA Sequencing: An Mmrf Commpass Analysis
2267 - Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical Trials
3174 - Whole Genome DNA Methylation Analysis of Commpass Identifies Biomarkers of Multiple Myeloma Survival
4464 - MAGE-A3 Promotes Chemotherapy Resistance and Proliferation in Multiple Myeloma through Regulation of BIM and p21Cip1